64th American Society of Hematology Annual Meeting and Exposition to Feature New Outcomes Research from Analysis Group

December 7, 2022

Analysis Group’s Health Care and HEOR, Epidemiology & Market Access practices will present 12 posters and two podium presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 10 to 13, 2022, in New Orleans, Louisiana, and online. Spanning topics such as chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, and B-, T-, and mantle-cell lymphomas, all sessions will take place at the Ernest N. Morial Convention Center.

The first podium presentation, “Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel or Other Donor Sources in Patients with Hematologic Malignancies: Comparison of Clinical Trial Results to Center for International Blood and Marrow Transplant Research Database Controls,” (poster 267) is coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice Presidents Gautam Sajeev and Yan Song, and Senior Analysts Chujun He and Chunyi Xu – and researchers from the Center for International Blood and Marrow Transplant Research and Gamida Cell.  The team will present on Saturday, December 10, from 2:30 to 2:45 p.m. in rooms 391–392. View the abstract here.

The second podium presentation, “Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib,” (poster 797) is coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Bruno Émond, Senior Research Professional Frédéric Kinkead, and Associate Laura Morrison – and researchers from the Atrium Health Levine Cancer Institute, Janssen Scientific Affairs, and the Baylor Scott & White Research Institute. The team will present on Monday, December 12, from 11:30 to 11:45 a.m. in rooms 388–390. View the abstract here.

Research poster presentations are as follows:

Saturday, December 10, 5:30–7:30 p.m. in Hall D

#1806: “Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, Senior Analyst Neema Lema, and Analyst Lisa Matay – in collaboration with researchers from Dana-Farber Cancer Institute and Merck. View the abstract here.

#1808: “Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia,” coauthored by an Analysis Group team – including Vice President Maral DerSarkissian, Associate Yan Chen, Senior Research Professional Louise Yu, and Senior Analyst Helen Guo – in collaboration with researchers from Memorial Sloan Kettering Cancer Center and AstraZeneca. View the abstract here.

#1878: “Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined by Cytogenetic Risk,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Maral DerSarkissian, Associate Mu Cheng, Senior Research Professional Annalise Hilts, and Analyst Justin Chun – in collaboration with researchers from The Tisch Cancer Institute, Takeda, and the Mayo Clinic. View the abstract here.

#2222: “Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Yan Song, Manager Ambika Satija, and Senior Analysts Ben Meade and Katherine Gaburo – in collaboration with researchers from Merck. View the abstract here.

#2265: “Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Maral DerSarkissian, Senior Associate Rose Chang, and Analyst Mingchen Ye – and researchers from the University of Pennsylvania Perelman Center for Advanced Medicine, Seagen, and Genesis Research. View the abstract here.

#2310: “Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020,” coauthored by an Analysis Group team – including Vice President Zheng-Yi Zhou, Manager Mo Zhou, and Senior Analysts Nathaniel Downes and Adina Zhang – in collaboration with researchers from the Mayo Clinic and Regeneron. View the abstract here.

Sunday, December 11, 6:00–8:00 p.m., in Hall D

#3534: “Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Yan Song, Manager Ambika Satija, and Senior Analysts Katherine Gaburo and Ben Meade – in collaboration with researchers from Merck. View the abstract here.

Monday, December 12, 6:00–8:00 p.m., in Hall D

#4343: “Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis,” coauthored by an Analysis Group team – including Vice President Lynn Huynh and Senior Analyst Churong Xu – in collaboration with researchers from Centre Léon Bérard, Fi-LMC group, Institut Universitaire du Cancer, Novartis, and Institut Bergonié. View the abstract here.

#4549: “Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Manager Guillaume Germain, Vice President François Laliberté, Associate Malena Mahendran, and Research Professional Ana Urosevic – in collaboration with researchers from Memorial Sloan Kettering Cancer Center, University of Rochester Medical Center, Washington University, University Hospital of Léon, GSK, and The University of Texas MD Anderson Cancer Center. View the abstract here.

#4902: “Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib,” coauthored by an Analysis Group team – including Vice President François Laliberté, Manager Enrico Zanardo, and HEOR Data Analyst Specialist Dominique Lejeune – in collaboration with researchers from Merck. View the abstract here.

#4911: “Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study,” coauthored by an Analysis Group team – including Vice President François Laliberté, Manager Enrico Zanardo, and HEOR Data Analyst Specialist Dominique Lejeune – in collaboration with researchers from Merck. View the abstract here.

#4954: “Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies by TP53 and IDH1/2 Mutation: Results from the AML Real World EvidenCe (ARC) Initiative,” coauthored by Managing Principal Annie Guérin, Associate Jessica Maitland, and a consortium of researchers from Rabin Medical Center, Dana-Farber Cancer Institute, Weill Cornell Medicine, O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, UNC Lineberger Comprehensive Cancer Center, Medical College of Wisconsin, Moffitt Cancer Center, University of Pennsylvania Perelman Center for Advanced Medicine, Tel Aviv Sourasky Medical Center, University of Colorado School of Medicine, Scripps MD Anderson Cancer Center, Hadassah-Hebrew University Medical Centre, Rambam Health Care Campus, Janssen Research and Development, AbbVie, Genentech, and Memorial Sloan Kettering Cancer Center. View the abstract here.

Read more about ASH’s Annual Meeting and Exposition